Are We Past the Checkpoint?

More than 10 years ago, the first immune checkpoint inhibitor (ICI) was approved in a monumental moment for the field of oncology, leading to eight approved drugs against three targets (PD-1/PD-L1, CTLA-4 and LAG3). While there has been success, the field has faced disproportionate setbacks, most recently multiple high-profile Phase 3 failures. The question remains, what is the future of the ICI space? What are the up-and-coming approaches to reactivating the body's own immune system?

This discussion will explore how the field of immuno-oncology has evolved, strategies to improve success in ICIs, including combination therapies, and entirely new approaches aimed to be more targeted and with reduced side effects.